Related Experiment Video
Updated: May 25, 2026
11:01
Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
[Expressive prosodic patterns in individuals with Alzheimer's disease]
Francisco Martínez-Sánchez1, Juan José García Meilán, Enrique Pérez
1Facultad de Psicología, Universidad de Murcia, 30100 Murcia, Spain. franms@um.es
Psicothema
|January 25, 2012
Summary
This study quantifies speech deficits in Alzheimer's patients using prosody analysis. Findings show reduced pitch and timing variations, leading to "flat" speech, potentially aiding diagnosis.
Area of Science:
- Neurolinguistics
- Computational Linguistics
- Gerontology
Context:
- Alzheimer's disease (AD) significantly impacts cognitive functions, including speech.
- Quantifying speech deficits in dementia of the Alzheimer's type (DAT) is crucial for clinical assessment.
- Existing methods may not fully capture the nuances of prosodic alterations in DAT.
Purpose:
- To introduce and validate a novel technique for quantifying speech deficits in DAT patients.
- To analyze prosodic speech production in DAT patients compared to healthy controls.
- To explore the diagnostic and prognostic potential of speech parameters in Alzheimer's disease.
Summary:
- Speech samples from DAT patients and controls were analyzed using the prosogram computational model.
- Variations in fundamental frequency (F0) and melodic styling were assessed.
- Significant differences were found, with DAT patients exhibiting reduced pitch variation and syllable timing, resulting in "flat" speech prosody.
Impact:
- The identified speech parameters may serve as valuable biomarkers for Alzheimer's disease.
- This technique could enhance clinical trials by providing objective measures of disease progression.
- Findings contribute to understanding the impact of DAT on speech production and communication.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.